Amarin (AMRN): Cowen Said At-Risk Launch of Hikma's Generic Vascepa is Unlikely
Tweet Send to a Friend
Cowen analyst Ken Cacciatore reiterated an Outperform rating and $10.00 price target on Amarin Corporation (NASDAQ: AMRN) after Hikma received ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
